Avacta Group transfer technology to BBI Solutions for manufacture of COVID-19 test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the appointment of BBI Solutions as manufacturing partner for the COVID-19 test. Alastair talk us through the details, how the prototype is working and the next steps in bringing it to market. Also discussed is the existing agreement with Daewoong Pharmaceutical which has been expanded to include the SARS-CoV-2 neutralising Affimer reagents and the development of the high throughput COVID-19 test with Adeptrix.

Avacta Group also announced that it has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Innovations in neutralising therapies

Coronaviruses are a large family of viruses that cause illnesses like the common cold, but can also cause more severe diseases such as Middle East Respiratory Syndrome (MERS) and Sever Acute Respiratory Syndrome (SARS). The novel

Avacta Group Plc

Biopharma update on the novel Coronavirus – July

Testing Therapies, Antivirals and Vaccines Avacta Group has partnered with the U.K. government’s CONDOR program to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry laboratory assay developed with Adeptrix. Adeptrix’s novel BAMS platform uses

Avacta Group Plc

Biopharma update on the novel Coronavirus

Testing Therapies, Antivirals and Vaccines Avacta Group entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert

Avacta Group Plc

Commercial potential for waste water Covid-19 detection

Life sciences business Avacta Group has become the second Yorkshire firm to partner with Integumen on Covid-19 detection systems for wastewater. The Wetherby-based listed firm has entered into a collaboration agreement with Integumen to evaluate its

Avacta Group Plc

preCISION and Affimer based cancer therapies

In this interview, Alastair Smith discusses our development of a rapid antigen test for SARS-Cov-2 and the progress of our preCISIONTM and Affimer® based cancer therapies. Watch below.  Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology

Avacta Group Plc

Avacta Group wins Small Cap award

Avacta Group has won Technology Company of the Year at the Small Cap 2020 Awards. Over 200 attendees, all supporters of the small cap community congregated online at the (optional) black tie event. Companies and advisors

Avacta Group Plc

How diagnostic test performance is measured

In this video, Avacta’s Chief Executive Officer Alastair Smith explains how diagnostic test performance is measured. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United

Avacta Group Plc

The Quest for a Cure

In 2003, the outbreak of severe acute respiratory syndrome (SARS) became the first pandemic of the 21st century and exemplified the rapid rate at which a virus can spread internationally. Originating in China, SARS quickly spread